

References

I-180

1. Aucatzyl® (obecabtagene autoleucel) suspension for intravenous infusion [package insert]. Autolus Inc., Gaithersburg, MD. 11/2024.
2. Roddie C, Dias J, O'Reilly MA, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory b-cell acute lymphoblastic leukemia. *J Clin Oncol*. 2021;39(30):3352-3363.
3. Roddie C, Sandhu K, Tholouli E, et al. Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study. *J Clin Oncol*. 2023.
4. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Obecabtagene Autoleucel.
5. Micromedex DrugDex Compendium®. 2024. Obecabtagene Autoleucel.